Form 8-K - Current report:
SEC Accession No. 0001640334-23-000800
Filing Date
2023-05-10
Accepted
2023-05-10 17:16:45
Documents
16
Period of Report
2023-05-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K lxrp_8k.htm   iXBRL 8-K 35993
2 PLACEMENT AGENCY AGREEMENT lxrp_ex102.htm EX-10.2 111674
3 PRESS RELEASE lxrp_ex991.htm EX-99.1 9836
  Complete submission text file 0001640334-23-000800.txt   316908

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lxrp-20230508.xsd EX-101.SCH 5720
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lxrp-20230508_lab.xml EX-101.LAB 14635
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE lxrp-20230508_cal.xml EX-101.CAL 898
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lxrp-20230508_pre.xml EX-101.PRE 9260
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE lxrp-20230508_def.xml EX-101.DEF 2099
10 EXTRACTED XBRL INSTANCE DOCUMENT lxrp_8k_htm.xml XML 3590
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Filer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
Type: 8-K | Act: 34 | File No.: 001-39874 | Film No.: 23907709
SIC: 2834 Pharmaceutical Preparations